You're here! If you're here right when we're going up, you've got any of the following: remarkable dedication to pop music, remarkable levels of New Year's Eve responsibility, a remarkable need to somehow convince your friends that yes, you did see all of the performances below. (If you're here later, you're probably still remarkable! Maybe not a remarkably early riser, though.)

Right now you've probably got a lot of things on your mind: 2012 resolutions, big plans, catching up on your friends' New Year's, your water intake, sleep. We get it. But since you're here, why not spare a few minutes seeing 2011 out one more time? Specifically, with some of the last performances of the year from New Year's Eve celebrations the New York streets and TV channels over. Below: Lady Gaga, LMFAO, Gym Class Heroes and a lot more of these people. Here's to many more performances in 2012.

LADY GAGA - HEAVY METAL LOVER, MARRY THE NIGHT, BORN THIS WAY

LMFAO - SHOTS

GYM CLASS HEROES - STEREO HEARTS

TAIO CRUZ - HANGOVER

JASON DERULO:

MAC MILLER - PARTY ON

GAGA DROPS THE BALL:

Hepatitis B vaccine plus lamivudine did not eliminate viral DNA.

Obesity, Fitness & Wellness Week September 4, 2004 2004 SEP 4 - (NewsRx.com & NewsRx.net) -- Combined recombinant hepatitis B vaccine and lamivudine therapy did not eliminate viral DNA in a patient with chronic hepatitis B.

"We report the first case of a woman having chronic hepatitis B treated with a combination therapy of recombinant hepatitis B vaccine and lamivudine for 18 months. The main aims of such a combined therapy were to assess whether the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the emergence of a mutant HBV and lead to sustained hepatitis B e antigen seroconversion with undetectable serum HBV DNA," scientists in Turkey report. in our site hepatitis b vaccine

"The data from the present case demonstrated that combination of anti-HBV vaccine and lamivudine did not eliminate viral DNA despite prolonged treatment and did not have any effect on preventing resistant-type HBV," stated Kendal Yalcin and colleagues at Dicle University. "Although the combined therapy failed to reach the therapeutic endpoints, it concerned a single and unique patient. Hepatitis B vaccine and lamivudine for HBV treatment should be further investigated in randomized controlled trials." Yalcin and associates published their study in the Southern Medical Journal (Late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B. Southern Med J, 2004;97(4):407-409). here hepatitis b vaccine

Publisher contact information for the Southern Medical Journal is: Lippincott, Williams, and Wilkins, 530 Walnut Street, Philadelphia, PA 19106-3621, USA.

The information in this article comes under the major subject areas of Hepatitis B Vaccine, Hepatitis B Virus, Hepatology, Immunology, Immunotherapy, and Virology.